Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Stephen Samuel Opat · SciRah

Researcher profile · Semantic Scholar

Stephen Samuel Opat

Monash Health
Monash University
Lymphoma and Related Diseases Registry

Share profile

Stephen Samuel Opat — researcher profile on SciRah

ORCID iD 0000-0002-0308-6458

h-index: 40
Works: 279
Citations: 9,827

Most-cited papers

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort
C. Tam, J. Allan, T. Siddiqi, T. Kipps +16 more
2022Blood230 citations Open access
Semantic Scholar
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
C. Tam, Jennifer R. Brown, B. Kahl, P. Ghia +27 more
2022The Lancet Oncology205 citations Open access
Semantic Scholar
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study
M. Dimopoulos, Stephen Samuel Opat, S. D'Sa, W. Jurczak +30 more
2023Journal of Clinical Oncology105 citations Open access
Semantic Scholar
Clinical pharmacology and PK/PD translation of the second-generation Bruton’s tyrosine kinase inhibitor, zanubrutinib
C. Tam, Y. Ou, J. Trotman, Stephen Samuel Opat
2021Expert Review of Clinical Pharmacology60 citations Open access
Semantic Scholar
Zanubrutinib: past, present, and future
C. Tam, Javier L. Munoz, John F. Seymour, Stephen Samuel Opat
2023Blood Cancer Journal53 citations Open access
Semantic Scholar
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study
Stephen Samuel Opat, A. Tedeschi, Bei Hu, K. Linton +22 more
2023Blood Advances39 citations Open access
Semantic Scholar
Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
T. Phillips, H. Chan, C. Tam, A. Tedeschi +10 more
2022Blood Advances38 citations Open access
Semantic Scholar
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia
Constantine S. Tam, Stephen Samuel Opat, S. D'Sa, W. Jurczak +32 more
2024Blood Advances35 citations Open access
Semantic Scholar
Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA
A. Herrera, S. Tracy, B. Croft, Stephen Samuel Opat +6 more
2022Blood Advances34 citations Open access
Semantic Scholar
CLL-137 SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib Versus Bendamustine + Rituximab (BR) in Patients With Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/ SLL).
B. Kahl, K. Giannopoulos, W. Jurczak, M. Šimkovič +25 more
2022Clinical Lymphoma, Myeloma & Leukemia25 citations
Semantic Scholar
Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma
J. Wong, Emily Gruber, B. Maher, M. Waltham +24 more
2022Leukemia25 citations Open access
Semantic Scholar
Chronic Lymphocytic Leukemia-Time to Care for the Survivors.
Pasquale L Fedele, Stephen Samuel Opat
2024Journal of Clinical Oncology22 citations
Semantic Scholar
Zanubrutinib, Alone and in Combination With Tislelizumab, for the Treatment of Richter Transformation of Chronic Lymphocytic Leukemia
C. Tam, J. Muñoz, G. Cull, Stephen Samuel Opat +7 more
2023HemaSphere22 citations Open access
Semantic Scholar
Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma
M. Tatarczuch, M. Waltham, J. Shortt, G. Polekhina +10 more
2023Blood Advances22 citations Open access
Semantic Scholar
P639: ZANUBRUTINIB (ZANU) VS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EXTENDED FOLLOW-UP OF THE SEQUOIA STUDY
T. Munir, M. Shadman, T. Robak, Jennifer R. Brown +31 more
2023HemaSphere18 citations Open access
Semantic Scholar
Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia
C. Tam, J. Trotman, Stephen Samuel Opat, J. Stern +5 more
2023Blood Advances16 citations Open access
Semantic Scholar
Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study
J. Allan, T. Siddiqi, T. Kipps, B. Kuss +13 more
2022Blood15 citations Open access
Semantic Scholar
Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry
M. Anderson, L. Berkahn, Che-Ah Y. Chan, Michael Dickinson +62 more
2022BMC Medical Research Methodology15 citations Open access
Semantic Scholar
A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with Non-Hodgkin Lymphoma (NHL) or Waldenström Macroglobulinemia (WM): Preliminary Data
J. Soumerai, M. Lasica, Stephen Samuel Opat, Che-Ah Y. Chan +8 more
2022Blood15 citations Open access
Semantic Scholar
Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study
C. Flowers, M. Matasar, A. Herrera, M. Hertzberg +10 more
2023Haematologica14 citations Open access
Semantic Scholar
Associations between Smoking and Alcohol and Follicular Lymphoma Incidence and Survival: A Family-Based Case-Control Study in Australia
M. Odutola, M. V. van Leeuwen, J. Turner, F. Bruinsma +14 more
2022Cancers14 citations Open access
Semantic Scholar
Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study
A. Barraclough, Shivam Agrawal, D. Talaulikar, Geoffrey Chong +18 more
2024Haematologica13 citations Open access
Semantic Scholar
Sonrotoclax and Zanubrutinib as Frontline Treatment for CLL Demonstrates High MRD Clearance Rates with Good Tolerability: Data from an Ongoing Phase 1/1b Study BGB-11417-101
J. Soumerai, C. Cheah, Mary Ann Anderson, M. Lasica +13 more
2024Blood13 citations
Semantic Scholar
Zanubrutinib Monotherapy for Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pooled Analysis of Three Studies
Wei Xu, Shen-Miao Yang, C. Tam, J. Seymour +18 more
2022Advances in Therapy13 citations
Semantic Scholar
Chronic lymphocytic leukaemia Australasian consensus practice statement
M. Anderson, R. Bennett, X. Badoux, Giles Best +21 more
2023Internal medicine journal (Print)12 citations Open access
Semantic Scholar
A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with CLL/SLL: Preliminary Data
Che-Ah Y. Chan, C. Tam, M. Lasica, E. Verner +6 more
2022Blood12 citations Open access
Semantic Scholar
BGB-11417-203: An ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia.
Hui-Peng Lee, Stephen Samuel Opat, J. Hrom, David Kliman +7 more
2024Journal of Clinical Oncology11 citations
Semantic Scholar
Monotherapy with Second-Generation BCL2 Inhibitor Sonrotoclax (BGB-11417) Is Well Tolerated with High Response Rates in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Data from an Ongoing Phase 1 Study
A. Tedeschi, C. Cheah, Stephen Samuel Opat, E. Verner +7 more
2023Blood11 citations Open access
Semantic Scholar
ZANUBRUTINIB (ZANU) VERSUS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT‐NAïVE (TN) CLL/SLL: EXTENDED FOLLOW‐UP OF THE SEQUOIA STUDY
M. Shadman, T. Munir, T. Roback, J. Brown +31 more
2023Hematological Oncology11 citations Open access
Semantic Scholar
Preliminary Safety and Efficacy Data from Patients (Pts) with Relapsed/Refractory (R/R) B-Cell Malignancies Treated with the Novel B-Cell Lymphoma 2 (BCL2) Inhibitor BGB-11417 in Monotherapy or in Combination with Zanubrutinib
C. Tam, E. Verner, M. Lasica, A. Arbelaez +8 more
2021Blood11 citations Open access
Semantic Scholar
MRD‐NEGATIVITY AFTER FRONTLINE DLBCL THERAPY: POOLED ANALYSIS OF 6 CLINICAL TRIALS
M. Roschewski, D. Kurtz, J. Westin, R. Lynch +14 more
2023Hematological Oncology10 citations Open access
Semantic Scholar
High risk of infection in ‘real‐world’ patients receiving ibrutinib, idelalisib or venetoclax for mature B‐cell leukaemia/lymphoma
Amanda Tey, James Schwarer, R. Raffa, Emily Shi +4 more
2023European Journal of Haematology9 citations Open access
Semantic Scholar
Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia
S. Mulligan, Stephen Samuel Opat, P. Marlton, B. Kuss +4 more
2022British Journal of Haematology9 citations
Semantic Scholar
SEQUOIA 5-year follow-up in arm C: Frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Constantine S. Tam, P. Ghia, M. Shadman, T. Munir +8 more
2025Journal of Clinical Oncology8 citations
Semantic Scholar
Long-term Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Who Received Zanubrutinib in the Phase 3 ASPEN Study: A Report from the Zanubrutinib Extension Study
S. D'Sa, M. Dimopoulos, W. Jurczak, P. Marlton +13 more
2024Blood8 citations
Semantic Scholar
Hematologic Malignancy: Who Cares in the End? A Retrospective Cohort Study of Markers of Quality End-of-Life Care.
B. Shaw, C. Parker, Stephen Samuel Opat, J. Shortt +1 more
2023The Journal of the National Comprehensive Cancer Network8 citations Open access
Semantic Scholar
Low mortality in vaccinated immunocompromised haematology patients infected with SARS‐CoV‐2
B. Shaw, J. Shortt, M. Low, Benjamin Rogers +7 more
2022Internal medicine journal (Print)8 citations Open access
Semantic Scholar
Long‐term outcomes of second‐line versus later‐line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis
Yu-Qin Song, K. Zhou, D. Zou, Dengju Li +18 more
2023Cancer Medicine7 citations Open access
Semantic Scholar
Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient Program
S. Mulligan, Stephen Samuel Opat, Che-Ah Y. Chan, B. Kuss +7 more
2022Leukemia and Lymphoma7 citations Open access
Semantic Scholar
PHASE 1 STUDY OF JNJ‐67856633, A FIRST‐IN‐HUMAN MALT1 INHIBITOR, IN RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
M. Hertzberg, M. Kalac, Che-Ah Y. Chan, V. Ribrag +20 more
2023Hematological Oncology6 citations Open access
Semantic Scholar
A phase 1, open-label, randomized drug–drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies
B. Tariq, Y. Ou, J. Stern, Vaibhav Mundra +7 more
2022Leukemia and Lymphoma6 citations Open access
Semantic Scholar
A Window Study of Acalabrutinib & Rituximab, Followed By Chemotherapy & Autograft (ASCT) in Fit Patients with Treatment Naïve Mantle Cell Lymphoma (MCL): First Report of the Investigator-Initiated Australasian Leukaemia & Lymphoma Group NHL33 ‘Wamm’ Trial
E. Hawkes, S. T. Lee, Leonid Churilov, T. Armytage +17 more
2023Blood5 citations Open access
Semantic Scholar
COVID-19 Infection in Patients With Chronic Lymphocytic Leukemia Receiving Acalabrutinib in the Phase 3B ASSURE Study
C. Niemann, Farrukh T. Awan, L. Fogliatto, E. Nikitin +5 more
2022HemaSphere5 citations Open access
Semantic Scholar
Sustained efficacy of zanubrutinib (zanu) vs bendamustine + rituximab (BR) in treatment (tx)-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN SLL/CLL) and continued favorable survival in non-randomized patients (pts) with del(17p): 6-year follow-up in the phase 3 SEQUOIA study
Constantine S. Tam, T. Munir, Tadeusz Robak, Jennifer R. Brown +12 more
2025Blood4 citations
Semantic Scholar
CRISTALLO: Results from a Phase III Trial of Venetoclax-Obinutuzumab Versus Fludarabine, Cyclophosphamide and Rituximab or Bendamustine-Rituximab in Patients with Untreated Chronic Lymphocytic Leukemia without Del(17p) or TP53 Mutations
Jeff P. Sharman, L. Laurenti, E. Ferrant, Luis Felipe Casado Montero +12 more
2024Blood4 citations Open access
Semantic Scholar
Correction: Zanubrutinib: past, present, and future
Constantine S. Tam, Javier L. Munoz, J. Seymour, Stephen Samuel Opat
2023Blood Cancer Journal4 citations Open access
Semantic Scholar
Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study
L. Sehn, M. Hertzberg, Stephen Samuel Opat, A. Herrera +11 more
2022Blood4 citations Open access
Semantic Scholar
Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre
C. Tam, G. Gregory, M. Ku, S. Fleming +21 more
2022Internal medicine journal (Print)4 citations
Semantic Scholar
P1161: ASPEN: LONG-TERM FOLLOW-UP RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR) IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM)
M. Dimopoulos, Stephen Samuel Opat, S. D'Sa, W. Jurczak +30 more
2022HemaSphere4 citations Open access
Semantic Scholar
A Description of the Type, Frequency and Severity of Infections Among Sixteen Patients Treated for T-Cell Lymphoma
T. Ko, C. Seah, M. Gilbertson, Zoe K. McQuilten +2 more
2021Journal of Hematology4 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

C. Tam×21
Invite
C. Tam — researcher profile on SciRah
A. Tedeschi×12
Invite
A. Tedeschi — researcher profile on SciRah
J. Trotman×11
Invite
J. Trotman — researcher profile on SciRah
E. Verner×10
Invite
E. Verner — researcher profile on SciRah

×9

Invite

P. Ghia — researcher profile on SciRah

Invite

P. Marlton — researcher profile on SciRah

Invite

A. Cohen — researcher profile on SciRah

Invite

M. Lasica — researcher profile on SciRah

Invite

M. Tani — researcher profile on SciRah

Invite

B. Kuss — researcher profile on SciRah

Invite

M. Shadman — researcher profile on SciRah

Invite

M. Trněný — researcher profile on SciRah